m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00041)
Target Name | LCAT3 | ||||
---|---|---|---|---|---|
Gene Name | LCAT3 |
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
LCAT3
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | LCAT3 upregulation is attributable to N6-methyladenosine (m6A) modification mediated by methyltransferase like 3 (METTL3), leading to LCAT3 stabilization. LCAT3 as a novel oncogenic lncRNA in the lung, and validated the LCAT3-FUBP1-MYC axis as a potential therapeutic target for lung adenocarcinomas. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Lung adenocarcinoma | ICD-11: 2C25.0 | ||
In-vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
Calu-1 | Lung squamous cell carcinoma | Homo sapiens | CVCL_0608 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HOP-62 | Lung adenocarcinoma | Homo sapiens | CVCL_1285 | |
In-vivo Model | For the in vivo tumorigenicity assay, female BALB/c nude mice (ages 4-5 weeks) were randomly divided into two groups (n = 6/group). Calu1 cells (4 × 106) that had been stably transfected with sh-LCAT3 or scramble were implanted subcutaneously into the nude mice. Tumor growth was measured after one week, and tumor volumes were calculated with the following formula: Volume (cm3) = (length × width2)/2. After four weeks, the mice were euthanized, and the tumors were collected and weighed. For the in vivo tumor invasion assay, 1.2 × 106 scramble or shLCAT3 cells were injected intravenously into the tail vein of nude mice (n = 6/group). 1.5 mg luciferin (Gold Biotech, St Louis, MO, USA) was administered once a week for 4 weeks, to monitor metastases using an IVIS@ Lumina II system (Caliper Life Sciences, Hopkinton, MA, USA). | |||
Lung cancer [ICD-11: 2C25]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | LCAT3 upregulation is attributable to N6-methyladenosine (m6A) modification mediated by methyltransferase like 3 (METTL3), leading to LCAT3 stabilization. LCAT3 as a novel oncogenic lncRNA in the lung, and validated the LCAT3-FUBP1-MYC axis as a potential therapeutic target for lung adenocarcinomas. | |||
Responsed Disease | Lung adenocarcinoma [ICD-11: 2C25.0] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
In-vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
Calu-1 | Lung squamous cell carcinoma | Homo sapiens | CVCL_0608 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HOP-62 | Lung adenocarcinoma | Homo sapiens | CVCL_1285 | |
In-vivo Model | For the in vivo tumorigenicity assay, female BALB/c nude mice (ages 4-5 weeks) were randomly divided into two groups (n = 6/group). Calu1 cells (4 × 106) that had been stably transfected with sh-LCAT3 or scramble were implanted subcutaneously into the nude mice. Tumor growth was measured after one week, and tumor volumes were calculated with the following formula: Volume (cm3) = (length × width2)/2. After four weeks, the mice were euthanized, and the tumors were collected and weighed. For the in vivo tumor invasion assay, 1.2 × 106 scramble or shLCAT3 cells were injected intravenously into the tail vein of nude mice (n = 6/group). 1.5 mg luciferin (Gold Biotech, St Louis, MO, USA) was administered once a week for 4 weeks, to monitor metastases using an IVIS@ Lumina II system (Caliper Life Sciences, Hopkinton, MA, USA). | |||